GeneOne Life Science, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 309.45 million compared to KRW 149.88 million a year ago. Net loss was KRW 13,197.23 million compared to KRW 10,973.53 million a year ago. Basic loss per share from continuing operations was KRW 171 compared to KRW 142 a year ago. Diluted loss per share from continuing operations was KRW 171. Basic loss per share was KRW 171 compared to KRW 141 a year ago.
For the six months, sales was KRW 541.22 million compared to KRW 299.76 million a year ago. Net loss was KRW 26,409.37 million compared to KRW 15,595.36 million a year ago. Basic loss per share from continuing operations was KRW 341 compared to KRW 201 a year ago. Diluted loss per share from continuing operations was KRW 341 compared to KRW 201 a year ago. Basic loss per share was KRW 341 compared to KRW 201 a year ago.